Modified polynucleotides for the production of secreted proteins
US10703789B2 · kind B2 · utility
34Cited by
33References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2019 |
| Grant date | Jul 7, 2020 |
| Priority date | — |
| Expiry date | Jun 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.